<DOC>
	<DOCNO>NCT02925416</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability two 1200-mg IV infusion oritavancin administer one week apart .</brief_summary>
	<brief_title>Safety Either Single Two IV Doses Orbactiv Subjects With ABSSSI</brief_title>
	<detailed_description>Clinical study adult subject ABSSSI demonstrate single 1200-mg IV dose oritavancin clinically non-inferior , well tolerate , similar safety profile 7 10 day IV vancomycin treatment . The 1200-mg dose oritavancin United States ( US ) approve therapeutic dose . Subjects ABSSSI enrol study obtain safety information two 1200-mg IV infusion oritavancin administer one week apart . The safety information include potential antibody production follow two 1200-mg IV infusion oritavancin . This study randomize , double-blind study . Subjects randomize receive either two dos oritavancin one dose oritavancin single dose placebo one week apart order obtain safety information . This safety information include information regard potential antibody production follow one two dos 1200 mg oritavancin .</detailed_description>
	<mesh_term>Skin Diseases</mesh_term>
	<mesh_term>Skin Diseases , Bacterial</mesh_term>
	<mesh_term>Oritavancin</mesh_term>
	<criteria>Diagnosis ABSSSI ( wound infection , Cellulitis/erysipelas , cutaneous abscess ) suspect confirm caused Grampositive pathogen require IV therapy Able give informed consent willing comply require study procedure Infections associate , close proximity , prosthetic device Severe sepsis refractory shock Known suspect bacteremia time screen ABSSSI due associate following : Infections suspect documented cause Gramnegative pathogen ( i.e. , human animal bite , injury contaminate fresh salt water , external malignant otitis ) Wound infection ( surgical traumatic ) abscesses Gramnegative pathogen Diabetic foot infection ( infection extend distal malleoli subject diabetes mellitus peripheral neuropathy and/or vascular insufficiency ulceration foot ) Concomitant infection another site include secondary ABSSSI lesion ( e.g. , septic arthritis , endocarditis , osteomyelitis ) Infected burn A primary infection secondary preexisting skin disease associate inflammatory change atopic dermatitis , eczema , hidradenitis suppurativa Decubitus chronic skin ulcer , ischemic ulcer due peripheral vascular disease ( arterial venous ) Any evolve necrotizing process ( i.e. , necrotizing fasciitis ) , gangrene , infection suspect proven caused Clostridium specie ( e.g. , crepitance examination ABSSSI site and/or surround tissue ( ) radiographic evidence subcutaneous gas proximity infection ) Infections know cause Grampositive organism vancomycin minimum inhibitory concentration ( MIC ) &gt; 2 μg/mL clinically fail prior therapy glycopeptides Catheter site infection Currently receive chronic systemic immunosuppressive therapy chemotherapy prednisone ( prednisone nonimmunosuppressive dos ≤15 mg/day permit ) Subjects likely need treatment IV unfractionated heparin sodium within 48 hour oritavancin administration Last known cluster differentiation 4 ( CD4 ) count &lt; 200 cells/mm3 subject know human immunodeficiency virus ( HIV ) /acquired immune deficiency syndrome ( AIDS ) Neutropenia absolute neutrophil count ( ANC ) &lt; 500 cells/mm3 Significant lifethreatening condition ( e.g. , endocarditis ) would confound interfere assessment safety Women pregnant nursing , childbearing potential unwilling use least 2 acceptable method birth control : ( e.g. , prescription oral contraceptive , contraceptive injection , contraceptive patch , intrauterine device , barrier method ( ) male partner sterilization ) . Women ≥2 year postmenopausal surgically sterile exempt exclusion History immunerelated hypersensitivity reaction glycopeptides ( vancomycin , televancin , daptomycin , dalbavancin ) excipients . Note : subject histaminelike infusion reaction glycopeptide excluded Subjects unwilling forego blood and/or blood product donation least 1 month initiation oritavancin dose Treatment investigational medicinal product within 30 day 5 halflives , whichever longer , enrollment duration study Investigational device present , remove within 30 day enrollment , presence devicerelated infection Subjects investigator considers unlikely adhere protocol , comply oritavancin administration , complete clinical study ( e.g. , unlikely survive 90 day initiation oritavancin dose ) Prior exposure oritavancin alone combination another product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>